Free Trial
NASDAQ:CBUS

Cibus 11/7/2024 Earnings Report

Cibus logo
$1.42 +0.07 (+5.19%)
Closing price 09/19/2025 04:00 PM Eastern
Extended Trading
$1.43 +0.01 (+0.70%)
As of 09/19/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cibus EPS Results

Actual EPS
$0.06
Consensus EPS
-$0.89
Beat/Miss
Beat by +$0.95
One Year Ago EPS
-$1.59

Cibus Revenue Results

Actual Revenue
$1.67 million
Expected Revenue
$0.47 million
Beat/Miss
Beat by +$1.20 million
YoY Revenue Growth
N/A

Cibus Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Cibus' Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Cibus Earnings Headlines

Contrasting Local Bounti (NYSE:LOCL) and Cibus (NASDAQ:CBUS)
Your Bank Account Is No Longer Safe
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.tc pixel
See More Cibus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cibus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cibus and other key companies, straight to your email.

About Cibus

Cibus (NASDAQ:CBUS) is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships. Cibus collaborates with seed companies, growers and research institutions to advance commercial trait pipelines for crops such as canola, pennycress and potato. By applying its RTDS technology, Cibus aims to shorten development timelines and reduce regulatory complexity compared with traditional genetic modification approaches.

Headquartered in San Diego, California, Cibus serves customers and partners across North America and Europe. The company maintains research and development facilities dedicated to molecular biology, genomics and field-based trait evaluation. Through strategic alliances, Cibus has expanded its global footprint, offering tailored solutions to support sustainable agriculture and meet evolving market needs.

Cibus is led by an experienced management team with deep expertise in agricultural biotechnology, genomics and crop sciences. The leadership group guides the company’s efforts to bring innovative, non-transgenic trait solutions to market, positioning Cibus at the forefront of the next generation of precision breeding technologies.

View Cibus Profile

More Earnings Resources from MarketBeat